# Sasanlimab

Source: https://onco.cc/drugs/sasanlimab/  
OnCo record `sasanlimab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Sasanlimab is an experimental monoclonal antibody from Pfizer in phase 3 trials for bladder & urothelial cancer, aimed at PD-1 and PD-L1.

## Summary

Sasanlimab (PF-06801591) is a monoclonal antibody developed by Pfizer. Its targets are PD-1 and PD-L1 (the sponsor names PD-1). The sponsor states: A monoclonal antibody that blocks the interaction between PD-1 and its ligands PD-L1/PD-L2. ClinicalTrials.gov describes the intervention as: A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PD-L1/PD-L2. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT04165317 (A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer), in bladder & urothelial cancer. The largest, NCT04165317, plans to enrol 1068 participants (actual) with primary completion was scheduled for 2024-12-02 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: PF-06801591
- Modality: monoclonal antibody
- Mechanism: A monoclonal antibody that blocks the interaction between PD-1 and its ligands PD-L1/PD-L2.

## Sources

- ClinicalTrials.gov: trials of Sasanlimab: https://clinicaltrials.gov/search?intr=Sasanlimab

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- targets: [PD-1](https://onco.cc/targets/pd1/), [PD-L1](https://onco.cc/targets/pdl1/), [PDCD1LG2](https://onco.cc/targets/pdcd1lg2/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)
- trials: [A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer](https://onco.cc/trials/nct04165317/)

---
JSON: https://onco.cc/api/v1/entities/sasanlimab.json